Superbugs are dangerous because they’ve developed the ability to survive the drugs designed to kill them, turning once-treatable infections into potentially life-threatening ones. In 2019 alone, nearly 5 million deaths worldwide were associated with drug-resistant bacterial infections, and roughly 1.27 million of those deaths were directly caused by resistance. These aren’t exotic diseases. They’re common infections, urinary tract infections, pneumonia, bloodstream infections, that simply stop responding to antibiotics.
How Bacteria Outsmart Antibiotics
Antibiotics work by targeting specific parts of a bacterium: its cell wall, its ability to reproduce, or proteins it needs to survive. Superbugs have evolved several strategies to neutralize these attacks, and a single bacterium can use more than one at a time.
Some bacteria change their outer surface so the antibiotic can no longer latch on. Others produce tiny pumps in their cell walls that actively push the drug back out before it can do any damage. Some manufacture enzymes that chop the antibiotic molecule apart, rendering it useless. And some simply build workarounds, developing new internal processes that bypass whatever the drug was trying to disrupt. These defenses aren’t rare mutations. Bacteria reproduce quickly, and they can also pass resistance genes to neighboring bacteria, meaning a defense that evolves in one species can spread to another.
The Infections Doctors Worry About Most
Not all superbugs are equally threatening. The CDC tracks several drug-resistant pathogens found primarily in healthcare settings, including MRSA (methicillin-resistant Staphylococcus aureus), carbapenem-resistant Enterobacterales (CRE), vancomycin-resistant Enterococcus (VRE), and a drug-resistant fungus called Candida auris. CRE is sometimes called a “nightmare bacteria” because carbapenems are among the last-resort antibiotics, so when they fail, very few options remain.
MRSA is probably the most widely recognized superbug. It causes skin infections, pneumonia, and bloodstream infections that don’t respond to standard antibiotics. But the growing concern is around gram-negative bacteria like CRE and drug-resistant Pseudomonas, which have an extra outer membrane that makes them naturally harder to treat and gives them a built-in advantage for developing further resistance.
Why Routine Medical Care Is at Stake
The danger of superbugs extends far beyond the infections they cause directly. Modern medicine depends on antibiotics working reliably. Before surgery, patients receive preventive antibiotics to ward off infection at the incision site. Cancer patients undergoing chemotherapy, which suppresses the immune system, rely on antibiotics to keep opportunistic bacteria in check. Joint replacements, C-sections, organ transplants: all of these carry infection risk that antibiotics are supposed to manage.
That safety net is fraying. A modeling study published in The Lancet Infectious Diseases estimated that between 39% and 51% of bacteria causing surgical site infections in the U.S. are already resistant to the standard preventive antibiotics used during those procedures. For infections after chemotherapy, that figure is about 27%. If antibiotic effectiveness dropped by just 30%, the U.S. could see an additional 120,000 surgical and post-chemotherapy infections per year and 6,300 extra deaths from those infections alone. A 70% drop in effectiveness would push that to 280,000 additional infections and 15,000 deaths.
A Shrinking Arsenal of New Drugs
One reason superbugs are so alarming is that the pipeline for new antibiotics is thin and getting thinner. The number of antibiotics in clinical development dropped from 97 in 2023 to 90 in 2025. Since mid-2017, only 17 new antibiotics targeting dangerous resistant bacteria have been approved for use, and just two of those represent genuinely new types of drugs rather than variations on existing ones.
Developing antibiotics is expensive, and unlike drugs for chronic conditions that patients take for years, antibiotics are used for short courses. That makes them a poor investment for pharmaceutical companies, so fewer resources go into creating them. Meanwhile, bacteria keep evolving. The result is an arms race where one side has largely stopped building new weapons.
How Superbugs Spread
Hospitals are the primary breeding ground for drug-resistant infections. Sick patients with weakened immune systems, frequent antibiotic use, and close quarters create ideal conditions for resistant bacteria to thrive and jump between people. Contaminated surfaces, medical equipment, and the hands of healthcare workers are all common transmission routes.
But superbugs don’t stay in hospitals. Research across multiple countries, including Singapore, Bangladesh, India, Lebanon, and Spain, has found carbapenem-resistant bacteria in raw hospital sewage that flows into the broader environment. Once in community water systems, resistant bacteria can spread to people who have never set foot in a hospital. This is why drug resistance is a population-level problem, not just a concern for hospitalized patients.
The Diagnostic Problem
When someone arrives at a hospital with a serious infection, doctors often can’t immediately tell whether the bacteria involved are drug-resistant. Standard lab cultures can take one to four days to identify which antibiotics will work. Newer rapid tests aim to deliver results within four to six hours, but they aren’t available everywhere. In the meantime, doctors typically prescribe broad-spectrum antibiotics as a best guess. If the bacteria turn out to be resistant, the patient has lost valuable time on a drug that wasn’t working. And the unnecessary broad-spectrum use itself contributes to more resistance.
One study found that when rapid testing was available, the proportion of patients receiving unnecessary broad-spectrum antibiotics dropped from 30% to 12.5%. Faster identification saves lives and slows resistance, but the technology hasn’t been widely adopted yet.
The Economic and Human Cost
Drug-resistant infections cost roughly $700 billion in global hospital expenses in 2019. On top of that, excess deaths from these infections resulted in an estimated $193 billion in lost productivity. Per patient, a resistant infection can add up to $29,000 in additional hospital costs compared to a treatable one, driven by longer stays, more intensive care, and the need for expensive second- and third-line drugs.
The human projections are stark. A major analysis published in The Lancet in 2024 modeled the trajectory of antimicrobial resistance through 2050. The roughly 1.27 million deaths directly attributable to resistant bacteria in 2019 are expected to climb significantly as resistance spreads and the population ages. Every year that passes without effective new drugs or better stewardship of existing ones narrows the margin between manageable problem and global health crisis.